Detail of "5051-62-7"

Reference

Regulation of adipose tissue metabolism via adrenergic mechanisms: actions of alpha-adrenoceptor agonists on lipolysis in hamster fat cells

Regulation of adipose tissue metabolism via adrenergic mechanisms: actions of alpha-adrenoceptor agonists on lipolysis in hamster fat cells.Some chemicals with cas registry numbers like 51-41-2 and 7683-59-2 are also used. Curtis-Prior, P. B.; Tan, Suon (Cent. Rech. Courtaboeuf, Inst. Henri Beaufour, Les Ulis 91940, Fr.). Int. J. Obes., 7(4), 299-305 (English) 1983. CODEN: IJOBDP. ISSN: 0307-0565. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) The effects of two a1-adrenergic agonists (phenylephrine [59-42-7], cirazoline [59939-16-1]) and two a2-adrenergic agonists (clonidine [4205-90-7], guanabenz [5051-62-7]) were investigated on lipolysis stimulated by noradrenaline [51-41-2], isoprenaline [7683-59-2], dibutyryl cAMP (dbcAMP) [362-74-3] or methylisobutylxanthine (MIX) [28822-58-4] in hamster adipose cells, in vitro. Phenylephrine enhanced basal lipolysis and that stimulated by dbcAMP and MIX, whereas cirazoline showed no measurable effects. Clonidine produced a slight but significant decrease of basal lipolysis. Both clonidine and guanabenz (310-7M) provoked a similar and clear inhibition (50-60%) of MIX-stimulated lipolysis, compatible with the view that the a-adrenergic receptor of the hamster white fat cell is of the a2 type. Noradrenaline-stimulated lipolysis was unaffected, and isoprenaline-stimulated lipolysis moderately inhibited, by clonidine and guanabenz. Since the b-adrenergic lipolytic effects of noradrenaline are known to be assocd. with a simultaneous a-adrenergic inhibitory stimulus, and one possible explanation of the but moderate inhibition of isoprenaline-induced lipolysis could be simultaneous b-adrenergic stimulation (resulting in lipolysis), and a-adrenergic stimulation (inhibition of lipolysis), as with noradrenaline, the nature of isoprenaline as a pure b-adrenergic agonist requires clarification. .

Clinico-pharmacological evaluation of guanabenz in 10 healthy male volunteers

Clinico-pharmacological evaluation of guanabenz in 10 healthy male volunteers. Nakashima, Mitsuyoshi; Hashimoto, Hifakuni; Oguro, Katsuyoshi; Oguchi, Sadao; Uematsu, Toshihiko; Takiguchi, Yoshiharu; Kudo, Haruyoshi; Matsumura, Shinichi; Yokoyama, Nobuharu (Univ. Sch. Med., Hamamatsu Univ., Hamamatsu, Japan). Rinsho Yakuri, 14(4), 637-48 (Japanese) 1983.There are some reagents like 5051-62-7 is used in this study. CODEN: RIYADS. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The antihypertensive guanabenz (I) [5051-62-7] (8 mg, orally) given to volunteers was rapidly absorbed, reaching the max. plasma level at 2 h. The I level decreased with the half life of 5.37 h. The av. urinary I excretion in 48 h was 41.2% of the dose given, and I was mostly metabolized when excreted. Blood pressure decreased to the lowest level at 5 h. I caused a decrease in noradrenaline level in plasma. It inhibited the increase of adrenaline in plasma in exercising subjects. I had no significant effect on blood circulation. .